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Abstract
Background—Depression consistently predicts nonadherence to human immunodeficiency virus
(HIV) antiretroviral therapy, but which aspects of depression are most influential is unknown.
Such knowledge could inform assessments of adherence readiness and the type of depression
treatment to utilize.
Purpose—We examined how depression severity, symptom type and change over time relate to
adherence.
Methods—Microelectronic adherence and self-reported depression data from 1374 participants
across merged studies were examined with cross-sectional and longitudinal analyses. Depression
variables included a continuous measure, categorical measure of severity, cognitive and vegetative
subscales, and individual symptoms.
Results—At baseline, mean adherence was 69%, and 25% had mild/moderate and 18% had
severe depression. In cross-sectional multivariate analyses, continuous depression, cognitive
depressive symptoms and severe depression were associated with lower adherence. In longitudinal
analysis, reductions in both continuous and categorical depression predicted increased adherence.
Conclusions—The relationship between global continuous depression and nonadherence was
statistically significant, but relatively weak compared to that of cognitive depressive symptoms
and severe depression, which appear to pose strong challenges to adherence and call for the need
for early detection and treatment of depression.
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INTRODUCTION
Depressive symptoms are highly prevalent in individuals infected with the human
immunodeficiency virus (HIV). In a large nationally representative probability sample of
persons living with HIV in the U.S., 37% screened positive for depression using a self-report
(1). Rates of current clinical depression are much lower when diagnosed by clinical
structured interviews (2), but nonetheless are roughly two times greater in people living with
HIV than the general population (approximately 10% versus 5%), as determined by a meta-
analysis of published studies (3).
Depression has been associated with a threefold increase in nonadherence with medical
treatment recommendations in general (4), and HIV research has consistently shown
depression to be an impediment to HIV antiretroviral therapy (ART) adherence (5–9).
Depression is also associated with missed clinic appointments (6), failure to initiate ART
(10–12) or to enter into HIV care (13), virologic treatment failure (14), and provider
reluctance to prescribe ART for fear of it interfering with adherence (15–17). However,
studies to date have mostly examined the cross-sectional association between global
measures of depression and nonadherence in relatively small samples. Research on the
specific aspects of depression (e.g., type and severity of depressive symptoms) that drive its
effect on objectively measured adherence over time and in large samples are scarce. Greater
understanding of how these aspects of depression affect adherence can inform adherence
interventions that integrate depression treatment and decisions regarding ART initiation
among depressed patients (18).
There has been speculation, but little data, concerning whether specific types of depressive
symptoms are more or less associated with lapses in medication adherence. Both cognitive
and vegetative symptoms of depression may present challenges to adherence. For example,
cognitive symptoms such as low mood and loss of interest can result in loss of motivation
for daily activities, including taking one’s medication on schedule (19, 20). Poor
concentration can manifest as forgetfulness, which is the most frequently cited reason
patients give for missing doses of ART (7, 9, 20, 21). Vegetative symptoms such as sleep
disturbance and fatigue can wreak havoc with structured daily routines including dosing
regimens (22). Loss of appetite can make it a challenge to eat the food needed to properly
absorb medication and lead to patients skipping doses in an attempt to mitigate side effects
intensified by poor dietary intake. If either vegetative or cognitive depressive symptoms are
more strongly related to adherence, this can inform the nature of both the assessment and
treatment of depression that clinicians utilize to improve adherence.
For both assessment and intervention purposes, it is also important to understand whether
severity of depression is associated with nonadherence. Standardized depression rating
scales and diagnostic interviews provide a range of diagnostic levels of depression severity
based on diagnostic criteria or validated cut-off scores, from mild to moderate to severe
depression, and it is possible that these severity levels of depression may differentially
influence adherence. Yet we are unaware of published data that have carefully examined this
potentially important distinction. Some providers are reluctant to prescribe ART to
depressed patients, fearing that depression prevents a patient from being able to adhere well
enough to ward off developing drug resistance (15–17); knowing whether any level of
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depression, or only severe levels of depression, are associated with poor adherence could
thus inform decisions regarding adherence readiness and treatment initiation.
Longitudinal studies can shed further light on the relationship between depression and
nonadherence; however, few studies have adequate statistical power, longitudinal data or
precision of adherence measurement. While depression is commonly thought of as an
antecedent to nonadherence, the relationship between depression and adherence may be
bidirectional; depression may impede adherence and other health behaviors, and poor
adherence and associated effects on physical health may increase the risk for depression
(23). Studies of interventions targeting both depression and ART non-adherence have
resulted in mixed findings regarding whether changes in depression correspond to like
changes in adherence over time. Safren et al. conducted a small pilot study of cognitive-
behavioral counseling for depression and ART nonadherence and found that intervention
patients experienced a significant decrease in depression and increase in adherence over
time (18). In contrast, Antoni et al. found that beneficial effects of a cognitive-behavioral
stress management program on depressed mood were not associated with improved ART
adherence (24). Other studies have found that those receiving psychiatric care, including
antidepressants, and who presumably experience reduced depression, are more likely to be
prescribed ART and to be adherent to it (25–28).
In this paper we report findings from a secondary analysis of data merged from longitudinal
studies that measured ART adherence with electronic monitoring devices, considered to be
one of the most accurate, objective methods currently available (29). We examined multiple
measures of depression to assess whether the relationship between depression and
nonadherence differs by diagnostic levels of depressive severity, types of symptoms
(cognitive vs. vegetative), and specific individual depressive symptoms. We also examined
the relationship between changes in adherence and depression over time. Our hypotheses
included the following: 1) adherence will be significantly lower among individuals with
severe or moderate depressive symptoms as compared to those evidencing no depressive
symptoms; 2) cognitive depressive symptoms will be more strongly negatively correlated
with adherence compared to vegetative depressive symptoms; and 3) reduced depressive
symptoms over time will be associated with improved adherence.
METHODS
Data Source
Data are from the Multi-site Adherence Collaboration on HIV (MACH14), a project of
pooled data from 16 longitudinal studies that examined electronically monitored ART
adherence across 14 research sites in the United States. All studies received IRB approval
for their protocols and obtained written informed consent. The samples for these studies
were recruited between 1997 and 2009, and 12 evaluated an adherence intervention, while
the other 4 were observational studies. The analysis for this paper was performed with data
from the 10 studies included in the MACH14 dataset that had measures of depression. From
this dataset, 1374 participants (out of 2860 participants in the entire dataset) had both
depression and adherence measures available, and thus constituted the sample for this
analysis. The eligibility criteria varied across these studies, but eight of the ten studies were
performed with general HIV clinic populations (the other two consisted of drug users and
homeless or marginally housed); none specifically enrolled depressed patients. A more
detailed description of MACH14 is published elsewhere (30).
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Background characteristics—These included age, gender, race/ethnicity, education,
employment, sexual orientation, whether or not illicit drugs had ever been used in the past,
and CD4 count at study entry.
ART adherence—Electronic data monitoring caps were used to measure adherence in all
of the studies from which the data were drawn. These caps house an electronic chip that
records the exact time that the cap is unscrewed from the bottle. Participants were instructed
to remove the cap from the bottle at the time that they planned to ingest the medication and
to only remove one dose at a time. Adherence was operationalized as the percentage of
prescribed doses taken during the two weeks prior to the assessment (continuous variable),
and whether or not the participant had taken at least 90% of their prescribed doses (‘good’
adherence) during this time period (dichotomous variable)—a cutoff that is commonly used
in research and that represents a level of adherence needed to achieve sustained virologic
response (31, 32). The timing of when the doses were taken (i.e., cap removed from the
bottle) is not accounted for in these variables. The two-week observation period matches the
time frame used in the depression measures in half of the ten studies, with the other half
using past week as the time frame.
Depression—Four different depression measures were used across the 10 studies: four
used the Beck Depression Inventory- Version II (BDI-II; 33), one used the original version
of the BDI (34), three used the Center for Epidemiological Studies Depression Scale (CES-
D; 35), and two used the depression subscale of the Brief Symptom Inventory (BSI; 36). In
order to merge the depression data from all studies, we devised methods to compute a single
continuous measure, a single categorical measure that reflects established diagnostic levels
of depression, and single items for each depression symptom that was assessed.
The continuous measure of depression was created by converting data from each of the
different depression scales into standardized Z scores. The categorical measure of
depression severity was aggregated using published, previously validated ranges for each
depression scale. Both versions of the BDI have four validated score ranges that reflect
severity of depression (minimal, mild, moderate, severe), as does the CES-D (none, mild to
moderate, clinical depression, major depression). Level of depressive severity was collapsed
into three categories for each measure: the first level in the original classification of each
scale was labeled ‘none/minimal’, the second and third levels were combined to represent
‘mild/moderate’, and the fourth level was labeled ‘severe’. Data from the two studies that
used the BSI (n = 238) were not included when creating this variable, because the BSI does
not have validated cutoff scores for establishing severity levels.
Finally, to combine data with regard to individual depression symptoms we compared the
response formats representing the frequency of each item or symptom of each measure: the
BDI-I, BDI-II and CES-D use 4-point response scales, while the BSI uses a 5-point response
scale, but in all cases the range is from ‘not at all/not present’ to ‘all of the time/very
present’. The individual symptom data were converted to 4-point response scales from 0
‘not present’ to 3 ‘present most or all of the time’; for the BSI, the last two response levels
(‘quite a bit’ and ‘extremely’) were combined to represent ‘present most or all of the time’
in the new response format. If a scale had multiple items that represented a specific
symptom (e.g., items “loss of energy” and “tiredness or fatigue” from the BDI-II), an
average of these items was used to represent the symptom score.
Finally, with the converted single item scores, mean vegetative and cognitive subscales were
calculated, which is a common categorization of depression symptom type (37–40).
Symptoms included in the vegetative subscale were fatigue, loss of appetite or weight, sleep
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disturbance, and psychomotor agitation; cognitive symptoms included depressed mood, loss
of interest, suicidality, irritability, hopelessness, indecisiveness, poor concentration,
worthlessness, and guilt. The depression scales varied on the number of vegetative and
cognitive symptoms that were represented; therefore, the subscale scores represented the
mean of the number of items or symptoms that were measured.
Statistical Analysis
Baseline was defined as the first assessment in which data were collected for both adherence
and depression. Along with the baseline measures, data from the subsequent two follow-up
assessments (if available) that measured both constructs were used in the longitudinal
analysis. Descriptive statistics were calculated to examine the distributions of depression,
adherence and demographic characteristics. Bivariate analysis [Pearson correlation, two-
tailed t-test, analysis of variance (ANOVA), and Chi-Square] were used to examine the
relationships between the continuous (percentage of prescribed doses taken) and categorical
[good (>= 90% adherence) versus poor adherence] measures of adherence and the
depression variables. Multiple linear (continuous measure of adherence) and logistic
(dichotomous measure of adherence) regressions were used to model the associations with
depression at baseline, controlling for background characteristics; separate analyses were
conducted for the continuous measure of depression, the categorical measure of diagnostic
depressive severity, and the vegetative and cognitive subscales (which were placed in a
single model together).
To examine the longitudinal relationship between depression and adherence, repeated
measure mixed effects models (41, 42) were fitted to assess whether depression is associated
with adherence overtime, controlling for the number of weeks between the first and the third
time points, and background characteristics that were significantly associated with
adherence in any of the cross-sectional regression analyses. Separate models were fitted for
the continuous and categorical measures of depression.
RESULTS
Sample Description
The sample of 1374 participants had the following demographic and background
characteristics: mean age was 42.0 years (SD=8.1; range: 18–70), 67% were male, 42% self-
identified as heterosexual, 71% were ethnic minorities (including 48% African American
and 13% Hispanic), 22% did not graduate from high school, and 32% had a history of illicit
drug use. Average length of time since HIV diagnosis was 7.9 years (SD = 5.6) and mean
CD4 count was 372 cells/mm3 (SD=296). Mean ART adherence at baseline was 69% (SD =
34%), with 593 (43%) having “good” adherence (defined as taking at least 90% of
prescribed doses).
With regard to depression at baseline, the mean Z-score on the standardized continuous
depression measure was 0.87 (SD = 1.64), with a range of −1.31 to 7.72. Among the
subgroup of 1128 participants who were from studies that used a depression rating scale
with established diagnostic cutoff scores, 639 (57%) had none or minimal signs of
depression, 284 (25%) had mild to moderate depression, and 205 (18%) had severe
depressive symptomatology.
Bivariate Analysis of the Relationship Between Depression and Adherence
We first examined the relationship between nonadherence and the standardized continuous
measure of depression. Adherence was negatively correlated with depression, r (1365) =
−0.08, p < .01, and those with good adherence had significantly lower depression (mean =
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0.63, SD = 1.47) than those with poor adherence (mean = 1.06, SD = 1.73), t (1346) = 4.9, p
< .001.
We then assessed whether each specific depressive symptom, as well as vegetative and
cognitive symptom subscales, was related to nonadherence. Good adherence was associated
with lower levels of nearly every individual depression symptom (only irritability did not
differ between good and poor adherers), as well as lower vegetative and cognitive subscale
scores (see Table 1). However, while both the cognitive and vegetative subscales were
negatively correlated with the continuous measure of adherence, analysis of each specific
depressive symptom revealed that most of the cognitive symptoms (depressed mood, loss of
interest, hopelessness, guilt, poor concentration, and worthlessness) were significantly
correlated with nonadherence, whereas fatigue was the only vegetative symptom that was
significantly correlated with nonadherence (see Table 1).
When examining the categorical variable of depression, mean adherence was equivalent
between those with no depression (mean = 68%, SD = 34%) and mild to moderate
depression (mean = 68%, SD = 35%), but both of these levels were significantly higher than
what was measured in those with severe depression (mean = 57%, SD = 38%), F(2,1125) =
8.79, p < .001. Similarly, only 28% of those with severe depression had ‘good’ adherence,
compared to 40% and 44% of those with no and mild to moderate depression, respectively,
χ2(2,1128) = 15.0, p < .001.
Cross-Sectional Multivariate Analysis of the Relationship Between Depression and
Adherence
Linear regression analysis was used to examine the relationship between depression and the
continuous measure of adherence, with a separate model for the (1) continuous measure of
depression, (2) cognitive and vegetative symptom subscales, and (3) categorical measure of
depressive severity. In each model, background covariates included age, gender,
employment, race/ethnicity, sexual orientation, history of illicit drug use, and baseline CD4
count. Table 2 lists the results of each model.
In the model with the continuous measure of depression, greater depression was
significantly associated with lower adherence, beta (SE) = −.012 (.006), p < .05. In the
model with both vegetative and cognitive symptom subscales, greater cognitive depressive
symptoms were associated with lower adherence, beta (SE) = −.052 (.027), p < .05, but not
vegetative symptoms. In the third model, which included the categorical measure of
depression (with ‘none/minimal’ depression as the referent), only severe depression, beta
(SE) = −.090 (.038), p < .01, was associated with lower adherence.
Logistic regression analysis was then used to examine the relationship between depression
and ‘good’ versus ‘poor’ adherence, again with separate models for each of the depression
measures and inclusion of the background covariates (see Table 3). The same three
measures of depression were significantly associated with the categorical adherence measure
as were associated with the continuous adherence measure: continuous depression, cognitive
depressive symptoms and severe depression. In the model with the continuous measure of
depression, greater depression was associated with poor adherence, O.R. (CI) = .86 (.79, .
93), p < .001. In the model with vegetative and cognitive symptom subscale scores, greater
cognitive depressive symptoms but not vegetative symptoms were associated with poor
adherence, O.R. (CI) = .74 (.55, .99), p < .05. The model with the categorical measure of
depression showed that severe depression, O.R. (CI) = .51 (.34, .78), p < .05, was associated
with poor adherence, but not mild to moderate depression.
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Longitudinal Multivariate Analysis of the Relationship Between Changes in Depression
and Adherence
Repeated measures mixed effect models were fitted to examine whether the continuous
measure of depression was associated with nonadherence over time. Adherence levels at the
three time periods was the dependent variable, and the independent variables included the
measures of depression at the same time periods, the number of weeks from time one to time
three (average of 27 weeks; range: 8–36 weeks), and the background characteristics that
were found to be predictive of adherence in any of the cross-sectional regression models
described above (age, gender, race/ethnicity, sexual orientation, history of drug use, CD4
count). Results indicate that change in depression over time was significantly associated
with change in adherence, beta (SE) = −.015 (.005), p < .01, such that for every unit of
increase in depression, adherence decreased by 1.5%; the maximum effect of depression on
adherence was approximately 12% change in adherence, as 8 was the highest depression
score (see Table 4).
In the model with categorical depression measure, we converted the 3-level measure of
depressive severity into a binary variable—high (severe) versus low (no or mild/moderate)
depression—because no and mild/moderate depression were associated with equivalent
levels of adherence in the bivariate analysis. Greater depression over time was associated
with reduced adherence, beta (SE) = −.089 (.018), p < .001, with depression associated with
about a 9% reduction in adherence (see Table 4).
DISCUSSION
This study is one of the few to examine the relationship between depression and ART
nonadherence using specific types of depressive symptoms, a finer analysis of depressive
severity, and objective, electronically-monitored longitudinal adherence data. Like other
studies, our data show that global depression is associated with lower adherence (5–9), but
our findings also suggest that cognitive depressive symptoms affect adherence more than
vegetative symptoms, that severe depression impedes adherence whereas mild to moderate
depression appears not to, and that reduced depression over time is associated with
improved adherence.
While the relationship between the global continuous measure of depression and
nonadherence was statistically significant, the magnitude was relatively weak compared to
that of cognitive depressive symptoms and especially severe depression. This highlights the
value of a more nuanced measurement of depression. Researchers and clinicians who are
assessing the relationship between depression and ART adherence, or examining whether a
patient’s depressive symptoms may pose a challenge to adherence, should use measures of
depression that go beyond a global impression and reflect both symptom type and severity.
Both cognitive and vegetative symptoms were associated with lower adherence when
assessed globally in the bivariate analyses, but analyses involving individual symptoms
showed that most cognitive symptoms were correlated with nonadherence, while fatigue was
the only vegetative symptom associated with adherence. Consistent with our hypothesis that
cognitive symptoms would be more strongly associated with nonadherence, the multivariate
analysis, which controlled for covariates including CD4 count, showed that the cognitive
symptom subscale was associated with nonadherence but not the vegetative symptom
subscale. Most vegetative depressive symptoms overlap with those of medical illness and
are common among persons living with HIV (e.g., poor appetite, insomnia, fatigue) (43);
therefore, the presence of such physical symptoms may be due to HIV (and possibly higher
viral load resulting from nonadherence) or antiretroviral side effects (which may be related
to greater adherence) and thus relate to nonadherence differently and less robustly than
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cognitive symptoms of depression, and may be related to nonadherence independent of
depression (44).
We hypothesized that patients with either severe or mild to moderate depression would have
lower adherence compared to non-depressed patients, but our data revealed that only severe
depression was associated with nonadherence. This finding has implications for HIV clinical
management and ART access, as providers have shown a reluctance to prescribe ART to
patients with mental illness for fear that such patients will not be able to adhere well enough
and thus develop drug resistance (15–17). While patients with mild to moderate depressive
symptoms may need mental health treatment for their depression, our data suggest that these
patients are able to adhere as well to ART as patients without depression, and that it is only
when depressive symptoms become relatively severe, and presumably disruptive to overall
functioning, that adherence is negatively affected. Accordingly, measures of depression in
routine clinical practice must assess not only the presence of symptoms but also symptom
severity and frequency, and include a sufficient representation of cognitive depressive
symptoms. Routine screening of depression can be implemented with little need for limited
clinic resources as several self-administered depression measures have been validated and
successfully used with HIV patients (45).
As we had hypothesized, longitudinal analysis showed that changes in depression
correspond with changes in adherence. This finding suggests that depression treatment could
have indirect benefits on adherence. Only recently have studies examined the effects of
depression treatment on adherence, but there is some evidence that antidepressant treatment
(25, 28, 46) and cognitive behavioral therapy for depression (18) improve adherence among
depressed patients. It would be informative to know whether such benefits accrue even more
among patients who had more severe depression or patients whose cognitive symptoms of
depression are relieved. Similarly, interventions to improve adherence may indirectly lead to
improve mood and psychological well-being, and this warrants examination.
Limitations of the study include the reliance on self-report measures of depression that were
not uniform across studies. Although the BDI and CES-D depression scales have established
scoring cutoffs for determining diagnostic levels of depression, self-reports overestimate
psychopathology and hence our data would be strengthened if depression diagnoses had
been derived from diagnostic interviews (45). The use of data from several different scales
also introduces added variance into the analyses, although the content of the different
measures are very similar. It is worth noting that the ranges of depression scores were
relatively similar across the studies that comprised that dataset for this analysis, suggesting
that none of the studies was an outlier that may have disproportionately influenced the study
findings. Also, the depression measures do not screen for bipolar depression, which may
affect adherence differently than unipolar depression.
In conclusion, these findings provide further confirmation of the relationship between
depression and poor ART adherence, as well as evidence that it is severe levels of
depression and cognitive depression symptoms that pose particular challenges to adherence.
Furthermore, changes in depression over time were associated with corresponding changes
in adherence. Our findings, together with the cited evidence that depression treatment
mitigates the harmful effects of depression on adherence, supports the importance of
integrating mental health care into HIV programs, routine periodic screening and early
detection of depression, and aggressive treatment of depression in people living with HIV.
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Table 2
Cross-sectional Multivariate Analyses Predicting Continuous ART Adherence in Models with Specific
Depression Measures
Beta When Different Depression Measures Are the Independent Variable
Variable Continuous Depression
Beta (SE)




Continuous depression −0.012 (.006)* --- ---
Vegetative depression --- 0.012 (.024) ---
Cognitive depression --- −0.052 (.027)* ---
Severe depression --- --- −0.090 (.038)**
Mild-mod. depression --- --- −0.025 (.028)
Age 0.002 (.001) 0.004 (.001)* 0.004 (.001)*
Female gender 0.004 (.025) 0.063 (.031)* 0.061 (.031)
Black race −0.035 (.025) −0.073 (.028)** −0.074 (.028)**
Hispanic ethnicity −0.080 (.034)* −0.054 (.042) −0.054 (.042)
Other race/ethnicity 0.015 (.036) −0.056 (.051) −0.056 (.051)
Gay/bisexual 0.089 (.024)*** 0.094 (.030)** 0.090 (.030)**
History of drug use −0.083 (.023)*** −0.040 (.026) −0.039 (.026)
Employed 0.016 (.023) −0.007 (.028) −0.009 (.028)
CD4 count 5.8 × 10−5 (3.3 × 10−5) 1.3 × 10−4 (3.8 × 10−5)*** 1.3 × 10−4 (3.8 × 10−5)***
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Table 3
Cross-sectional Multivariate Analysis Predicting Good vs. Poor ART Adherence in Models with Specific
Depression Measures
Beta When Different Depression Measures Are the Independent Variable
Variable Continuous Depression
O.R. (95% CI)




Continuous depression 0.86 (0.79, 0.93)*** --- ---
Vegetative depression --- 0.88 (.67, 1.14) ---
Cognitive depression --- 0.74 (.55, .99)* ---
Severe depression --- --- 0.51 (.34, .78)*
Mild-mod. depression --- --- 0.73 (.53, 1.02)
Age 1.00 (.99, 1.02) 1.01 (.99, 1.03) 1.01 (.99, 1.03)
Female gender 0.91 (.66, 1.25) 1.06 (.74, 1.52) 1.06 (.74, 1.53)
Black race 0.77 (.56, 1.05) 0.65 (.47, .91) 0.66 (.48, .93)
Hispanic ethnicity 0.57 (.37, .88)* 0.61 (.39, .96) 0.61 (.39, .94)
Other race/ethnicity 1.11 (.71, 1.74) 0.79 (.45, 1.41) 0.78 (.44, 1.39)
Gay/bisexual 1.41 (1.05, 1.89)* 1.38 (.98, 1.94) 1.37 (.97, 1.93)
History of drug use 0.53 (.40, .72)*** 0.66 (.48, .90)** 0.65 (.48, .89)**
Employed 1.07 (.80, 1.42) 1.09 (.79, 1.50) 1.10 (.80, 1.52)
CD4 count 1.00 (1.00, 1.00) 1.00 (1.00, 1.00) 1.00 (1.00, 1.00)
AIC for Model Fit (Smaller is better) 1417.411 1205.858 1205.973
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Table 4
Multivariate Regression Analysis of Change in ART Adherence Over Time in Models with Continuous and
Dichotomous Depression Measures
Variable Model with Continuous Depression
Beta (SE)
Model with Dichotomous Depression
Beta (SE)
Change in depression (continuous) −0.015 (.005)** ---
Change in depression (dichotomous) --- −0.089 (.018)***
Time (weeks) −0.001 (.000)* −0.001 (.000)*
Age 0.005 (.001)*** 0.005 (.001)***
Female gender −0.006 (.027) −0.005 (.027)
Black race −0.066 (.024)** −0.066 (.024)**
Hispanic ethnicity −0.080 (.034)* −0.081 (.034)*
Other race/ethnicity −0.009 (.041) −0.006 (.040)
Gay/bisexual 0.020 (.026) 0.024 (.026)
History of drug use −0.101 (.021)*** −0.101 (.021)***
CD4 count 1.7 × 10−4 (3.4 × 10−5)*** 1.5 × 10−4 (3.4 × 10−5)***
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